J. Lipid Res. Please sign the JLR Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

A more recent version of this article appeared on February 1, 2005

Papers In Press, published online ahead of print December 1, 2004
J. Lipid Res., doi:10.1194/jlr.M400438-JLR200
This Article
Right arrow Full Text (Accepted Manuscript)
Right arrow All Versions of this Article:
M400438-JLR200v1
46/2/350    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burgess, J. W.
Right arrow Articles by Sparks, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burgess, J. W.
Right arrow Articles by Sparks, D. L.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Submitted on November 3, 2004
Revised on December 1, 2004
Accepted on November 22, 2004

Phosphatidylinositol raises HDL cholesterol levels in humans

Jim W. Burgess, Tracey A. M. Neville, Patricia Rouillard, Zdena Harder, Donald S. Beanlands, and Daniel L. Sparks

Lipoprotein and Atherosclerosis Research Group, University of Ottawa Heart Institute, Ottawa, Ontario K1Y4W7

Corresponding Author: dsparks{at}ottawaheart.ca

Studies have shown that phosphatidylinositol (PI) can stimulate reverse cholesterol transport by enhancing the flux of cholesterol into HDL and by promoting the transport of HDL-cholesterol to the liver and bile. The goal of this study was to determine the safety and therapeutic value of PI following oral administration to normolipidemic human subjects. We performed a randomized 2 week study in 16 normolipidemic subjects. Subjects received either 2.8 g or 5.6 g of PI, with or without food. PI was well tolerated by all subjects. PI significantly affected the levels of HDL-C and triglyceride in the plasma of subjects receiving PI with food. The lower dose showed a 13% increase in HDL-C, while those on the high dose showed an increase of 18% over the 2 week period. Both low and high dose groups showed significant elevations in plasma apoA-I. The high dose of PI also decreased plasma triglycerides by 36% in the fed subjects. The data suggest that after only 2 weeks, PI may have a comparable therapeutic value to niacin, with negligible side effects.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 JAMAHome page
I. M. Singh, M. H. Shishehbor, and B. J. Ansell
High-Density Lipoprotein as a Therapeutic Target: A Systematic Review
JAMA, August 15, 2007; 298(7): 786 - 798.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
D. Duffy and D. J. Rader
Emerging Therapies Targeting High-Density Lipoprotein Metabolism and Reverse Cholesterol Transport
Circulation, February 28, 2006; 113(8): 1140 - 1150.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.